Want to see FHTX full AI Analyst Report?
FHTX Stock Chart & Stats
$6.69
$0.35(7.22%)
At close: 4:00 PM EDT
$6.69
$0.35(7.22%)
Day’s Range― - ―
52-Week Range$1.79 - $7.61
Previous Close$5.36
Volume159.32K
Average Volume (3M)1.07M
Market Cap
$109.86M
Enterprise Value$220.19M
Total Cash (Recent Filing)$167.58M
Total Debt (Recent Filing)$43.10M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Nov 10, 2026EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.99
Shares Outstanding59,385,315
10 Day Avg. Volume858,455
30 Day Avg. Volume1,067,953
Financial Highlights & Ratios
PEG Ratio0.18
Price to Book (P/B)-3.13
Price to Sales (P/S)11.00
P/FCF Ratio-3.95
Enterprise Value/Market Cap2.00
Enterprise Value/Revenue5.99
Enterprise Value/Gross Profit14.03
Enterprise Value/Ebitda-3.53
Forecast
1Y Price Target
$5.00Price Target Upside-25.26% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering9
EPS Forecast (FY)-0.9
Revenue Forecast (FY)$28.72M
Bulls Say, Bears Say
Bulls Say
Proprietary Drug-discovery PlatformFoghorn’s proprietary chromatin-regulatory platform provides a differentiated foundation for discovering genetically defined cancer therapies. Its focus on selective degraders and induced-proximity approaches could support multiple programs, allowing platform value to extend beyond any single clinical candidate over the next several quarters.
Growing Collaboration-related RevenueRevenue growth demonstrates that Foghorn is generating increasing economic support from its development and collaboration activities despite remaining pre-commercial. A higher revenue base can help fund research, validate partner interest, and provide operating leverage if priority programs advance successfully.
Cost Reduction Extends Cash RunwayThe restructuring aligns the cost base with a narrower set of priority programs and gives management more time to generate clinical or partnering milestones. Extending runway reduces near-term financing pressure and preserves the ability to continue developing wholly owned assets through multiple catalysts.
Bears Say
Persistent Losses And Cash BurnLarge recurring losses and substantial operating cash outflows show that Foghorn’s development model currently consumes capital faster than it generates sustainable earnings. Continued burn can force additional financing or program prioritization, potentially limiting flexibility and creating dilution or funding risk.
Negative Equity And Meaningful DebtNegative equity leaves the company with a weak capital structure and little balance-sheet cushion against further operating losses. Meaningful debt adds financial obligations while the business remains unprofitable, increasing dependence on external capital and constraining choices during development setbacks.
Clinical Program Discontinued For Insufficient EfficacyEnding the FHD-909 collaboration removes a clinical development path and indicates that the SMARCA2/4 synthetic-lethality strategy did not meet efficacy expectations. The setback narrows near-term pipeline validation and places greater importance on earlier-stage wholly owned programs.
Foghorn Therapeutics News
FHTX FAQ
What was Foghorn Therapeutics’s price range in the past 12 months?
Foghorn Therapeutics lowest stock price was $1.79 and its highest was $7.61 in the past 12 months.
What is Foghorn Therapeutics’s market cap?
Foghorn Therapeutics’s market cap is $109.86M.
When is Foghorn Therapeutics’s upcoming earnings report date?
Foghorn Therapeutics’s upcoming earnings report date is Nov 10, 2026 which is in 21 days.
How were Foghorn Therapeutics’s earnings last quarter?
Foghorn Therapeutics released its earnings results on Aug 06, 2026. The company reported -$0.1 earnings per share for the quarter, beating the consensus estimate of -$0.245 by $0.145.
Is Foghorn Therapeutics overvalued?
According to Wall Street analysts Foghorn Therapeutics’s price is currently Overvalued.
Does Foghorn Therapeutics pay dividends?
Foghorn Therapeutics does not currently pay dividends.
What is Foghorn Therapeutics’s EPS estimate?
Foghorn Therapeutics’s EPS estimate is -0.25.
How many shares outstanding does Foghorn Therapeutics have?
Foghorn Therapeutics has 59,385,315 shares outstanding.
What happened to Foghorn Therapeutics’s price movement after its last earnings report?
Foghorn Therapeutics reported an EPS of -$0.1 in its last earnings report, beating expectations of -$0.245. Following the earnings report the stock price went up 14.139%.
Which hedge fund is a major shareholder of Foghorn Therapeutics?
Currently, no hedge funds are holding shares in FHTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Foghorn Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.00 (-25.26% Downside)
$5.00 (-25.26% Downside)
Blogger Sentiment
Neutral
FHTX Sentiment 67%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 37.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.4%
Last 30 Days ▼ 11.4%
Last 30 Days ▼ 11.4%
News Sentiment
Very Bearish
Bullish news 0%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-57.07%
12-Months-Change
Fundamentals
Return on Equity
72.64%
Trailing 12-Months
Asset Growth
-10.10%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Foghorn Therapeutics
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
FHTX Stock 12 Month Forecast
Average Price Target
$5.00
▼(-25.26% Downside)
Technical Analysis
Karyopharm Therapeutics
―
Fulcrum Therapeutics
―
Zentalis Pharmaceuticals
―
ALX Oncology Holdings
―
C4 Therapeutics
―
Ownership Overview
1.09% Insiders
10.37% Mutual Funds
46.15% Other Institutional Investors
36.03% Public Companies and
Individual Investors